Publication:
HIV vaccine research in Thailand: Lessons learned

dc.contributor.authorPunnee Pitisuttithumen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-07-12T02:31:00Z
dc.date.available2018-07-12T02:31:00Z
dc.date.issued2008-04-01en_US
dc.description.abstractThailand is the only country that has conducted two Phase III efficacy trials and ten other Phase I/II studies using various HIV-1 vaccine constructs. This outstanding record is the result of strong efforts and commitment among various partners, including policy makers, regulators, researchers and foreign collaborators. Recently, it has become apparent that hardly any new HIV/AIDS candidate vaccines are in the pipeline reaching the stage of clinical testing, especially a candidate vaccine that is suitable for Thailand and the surrounding region. However, many lessons learned can be utilized or modified for other vaccine trials, particularly vaccines against other infectious diseases prevalent in developing countries. © 2008 Future Drugs Ltd.en_US
dc.identifier.citationExpert Review of Vaccines. Vol.7, No.3 (2008), 311-317en_US
dc.identifier.doi10.1586/14760584.7.3.311en_US
dc.identifier.issn17448395en_US
dc.identifier.issn14760584en_US
dc.identifier.other2-s2.0-42049092979en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/19340
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=42049092979&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleHIV vaccine research in Thailand: Lessons learneden_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=42049092979&origin=inwarden_US

Files

Collections